PCI 3.06.26

Current Edition

Current Features

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Continue reading

Subsection - Oncology

Essential DMPK Strategies for IND Success

Continue reading

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

Continue reading

Upcoming Events

CPHI 2027
AI in Drug Discovery
Auto Draft
Auto Draft
Elrig
Auto Draft
DDL 2026
Biotechnology Show 13.02.26

Advertisement

Advertisement

A&M Stabtest April 26

Advertisement

Biopharma Group – 19th March 2025

Advertisement

Micron View

Advertisement

Bachem skyscraper

Navigo Proteins Appoints Dr. Florian Settele as Managing Director of Navigo Pure

Navigo Proteins announces the appointment of Dr. Florian Settele as Managing Director of Navigo Pure with immediate effect. In his role, Florian will navigate the company on its journey to further strengthen and expand its position as a provider of best‑in‑class affinity chromatography products. As such, Navigo Pure is committed to building a strong pipeline of catalogue and customised products that support robust, scalable and cost‑effective biopharmaceutical manufacturing.

Dr. Settele contributes his outstanding experience in the field. As Head of Navigo Pure, he evolved into a key player, securing and solidifying the success of the company’s business. His appointment marks the next step in the company’s continued evolution and growth.

“It is a privilege to take on this new responsibility as Managing Director of Navigo Pure,” said Dr. Florian Settele. “Having been part of the company’s journey for 15 years, I look forward to building on this strong foundation together with our team and further expanding Navigo Pure’s position as an innovative partner in downstream bioprocessing.”

“Florian’s appointment is a natural next step for Navigo Pure and for Navigo Proteins. He qualifies uniquely for this exciting position and will continue to structure and shape Navigo Pure’s future and success. I am more than happy to see him taking on this responsibility and leading Navigo Pure into its next chapter as Managing Director.” – Dr. Henning Afflerbach, CEO of Navigo Proteins.

Dr. Settele worked at the German Cancer Research Center (DKFZ) and received his PhD in Cell and Molecular Biology from the University of Heidelberg and later completed an MBA at HHL Leipzig Graduate School of Management. Since joining Navigo Proteins in 2011, he has contributed to the company in positions spanning research and development, external collaborations, commercial alliances and business unit leadership.

Advertisement

Richter: Wed 23 October 2024, 09:03

Advertisement

Aseptic Tech

Advertisement

Steribar – 12.05.2025

Advertisement

PharmExcel

Advertisement

Polypure hompage

Advertisement

Gen Xpro

Advertisement

Alphinity

Advertisement

Crown Bioscience

Advertisement

Shimadzu

Advertisement

CPC